PathAI and GlaxoSmithKline Sign Multi-Year Agreement to Accelerate Research and Drug Development

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

PathAI, a global leader in AI-powered pathology, and GlaxoSmithKline ( GSK ), today announced a strategic multi-year partnership to accelerate scientific research and drug development programs in oncology and non-alcoholic steatohepatitis (NASH) by leveraging PathAIs technologies in digital pathology including the use of PathAIs AIM-NASH tool.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, April 5, 2022
Information
Tags: 
Oncology, Data Management, Health, Technology, Clinical Trials, Pharmaceutical, Biotechnology, GSK, Fatty liver disease, Machine learning, Diagnosis, Multimedia, Pathology, AI, Cancer, Precision medicine, CEO, GlaxoSmithKline, NASH, Artificial intelligence, Drug discovery, Engineering, Deep learning, Patient, Partnership, Pharmaceutical industry, Medical device, Pathai
Geotags: 
UNITED STATES, NORTH AMERICA, MASSACHUSETTS, LONDON, BOSTON
⚠ generated by AI ↴
Organisation: 
PATHAI
Summary
Key Points: 
  • PathAI, a global leader in AI-powered pathology, and GlaxoSmithKline ( GSK ), today announced a strategic multi-year partnership to accelerate scientific research and drug development programs in oncology and non-alcoholic steatohepatitis (NASH) by leveraging PathAIs technologies in digital pathology including the use of PathAIs AIM-NASH tool.
  • View the full release here: https://www.businesswire.com/news/home/20220405005080/en/
    PathAI and GlaxoSmithKline Sign Multi-Year Agreement (Graphic: Business Wire)
    GSKs world-leading AI/ML capability, including our dedicated in-house hub in London, is applying a predictive and data-driven approach to drug discovery and clinical trials with the aim of improving the success rates of new medicines.
  • PathAI is a leading provider of AI-powered research tools and services for pathology.
  • Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine.


PathAI, a global leader in AI-powered pathology, and GlaxoSmithKline (GSK), today announced a strategic multi-year partnership to accelerate scientific research and drug development programs in oncology and non-alcoholic steatohepatitis (NASH) by leveraging PathAI’s technologies in digital pathology including the use of PathAI’s AIM-NASH tool.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220405005080/en/

PathAI and GlaxoSmithKline Sign Multi-Year Agreement (Graphic: Business Wire)

PathAI and GlaxoSmithKline Sign Multi-Year Agreement (Graphic: Business Wire)

“GSK’s world-leading AI/ML capability, including our dedicated in-house hub in London, is applying a predictive and data-driven approach to drug discovery and clinical trials with the aim of improving the success rates of new medicines. We look forward to leveraging both PathAI’s expertise and models to advance GSK’s proprietary AI models and focus on designing better models to deliver improved treatment options for patients with cancer and NASH,” said Kim Branson, SVP Global Head of Artificial Intelligence and Machine Learning at GSK.

“Our partnership will combine GSK and PathAI’s AI and platform engineering teams to scale algorithm development and enable the discovery of new insights that can be rapidly integrated into clinical trials,” said Andrew Beck, CEO and Co-founder of PathAI. “With our combined efforts, we aim to harness the power of machine learning to predict which patients will benefit from therapies in key high need areas.”

For more information, please visit: https://www.pathai.com/

About PathAI

PathAI is a leading provider of AI-powered research tools and services for pathology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning. Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine. To learn more, visit pathai.com.

Copyright: 
Copyright Business Wire 2022